MARKET

SLP

SLP

Simulations Plus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

70.73
-2.18
-2.99%
Opening 10:20 01/15 EST
OPEN
73.33
PREV CLOSE
72.91
HIGH
75.00
LOW
70.70
VOLUME
42.18K
TURNOVER
--
52 WEEK HIGH
83.78
52 WEEK LOW
26.00
MARKET CAP
1.41B
P/E (TTM)
138.66
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Simulations Plus Awards Infrastructure Improvement Grant to Makerere University Department of Pharmacology and Therapeutics
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of population pharmacokinetic and pharmacodynamic modeling and simulation services, today announced that its Cognigen division has awarded a grant to the Department of Pharmacology and Therapeutics at Makerere University in Kampala, Uganda, the country's largest and oldest institution of higher learning, to fund upgraded internet capabilities, ensuring access to Cognigen's KIWI(TM) platform. Access to this web-based knowledge-sharing platform will accelerate the University's pharmaceutical research efforts and quantitative approaches, including modeling and simulation.
BusinessWire · 1d ago
Simulations Plus (SLP) Stock Down Despite Q1 Earnings Beat
Zacks · 1d ago
Simulations Plus Enters New Funded Collaboration to Improve Lung Exposure Models For Pulmonary Infection Treatments
Integrated machine learning and PBPK/PD methods will support discovery and development activities Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation solutions for the pharmaceutical,
Benzinga · 3d ago
Simulations Plus to Present at 23rd Annual Needham Virtual Growth Conference
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O'Connor will present at the 23rd Annual Needham Virtual Growth Conference on Thursday, January 14, 2021, at 2:00 p.m. ET. In addition to his presentation, Mr. O'Connor will host one-on-one meetings throughout the day.
BusinessWire · 3d ago
Simulations Plus Enters New Funded Collaboration to Improve Lung Exposure Models for Pulmonary Infection Treatments
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to develop machine learning models and enhance physiologically based pharmacokinetics / pharmacodynamics (PBPK/PD) approaches for potential treatments of pulmonary infections.
BusinessWire · 3d ago
Simulations Plus declares $0.06 dividend
Simulations Plus (SLP) declares $0.06/share quarterly dividend, in line with previous.Forward yield 0.29%Payable Feb. 1; for shareholders of record Jan. 25; ex-div Jan. 22.See SLP Dividend Scorecard, Yield Chart, &
Seekingalpha · 3d ago
8-K: SIMULATIONS PLUS INC
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT (EDGAR Online via COMTEX) -- PURSUANT TO SECTION 13 OR 15(d) OF THE...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 3d ago
DJ Simulations Plus, Inc. CEO Shawn O'Connor on Q1 2021 Results -- Earnings Call Transcript >SLP
Dow Jones · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLP. Analyze the recent business situations of Simulations Plus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLP stock price target is 84.25 with a high estimate of 95.00 and a low estimate of 76.00.
EPS
Institutional Holdings
Institutions: 221
Institutional Holdings: 12.52M
% Owned: 62.71%
Shares Outstanding: 19.96M
TypeInstitutionsShares
Increased
68
1.32M
New
47
1.03M
Decreased
46
854.68K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.08%
Healthcare Equipment & Supplies
+0.40%
Key Executives
Chairman/Director
Walter Woltosz
Chief Executive Officer
Shawn O'Connor
Chief Financial Officer/Secretary
William Frederick
Corporate Executive
John DiBella
Independent Director
Lisa LaVange
Corporate Executive
Jill Fiedler-Kelly
Independent Director
John Paglia
Independent Director
David Ralph
Independent Director
Daniel Weiner
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
01/11/2021
Dividend USD 0.06
01/22/2021
10/13/2020
Dividend USD 0.06
10/23/2020
07/09/2020
Dividend USD 0.06
07/24/2020
04/09/2020
Dividend USD 0.06
04/23/2020
01/09/2020
Dividend USD 0.06
01/24/2020
10/14/2019
Dividend USD 0.06
10/24/2019
07/10/2019
Dividend USD 0.06
07/24/2019
04/09/2019
Dividend USD 0.06
04/23/2019
01/09/2019
Dividend USD 0.06
01/24/2019
10/22/2018
Dividend USD 0.06
10/31/2018
07/06/2018
Dividend USD 0.06
07/25/2018
04/09/2018
Dividend USD 0.06
04/24/2018
01/16/2018
Dividend USD 0.06
01/25/2018
11/01/2017
Dividend USD 0.06
11/10/2017
07/18/2017
Dividend USD 0.05
07/26/2017
04/26/2017
Dividend USD 0.05
05/04/2017
01/20/2017
Dividend USD 0.05
01/26/2017
10/31/2016
Dividend USD 0.05
11/08/2016
08/01/2016
Dividend USD 0.05
08/09/2016
04/22/2016
Dividend USD 0.05
04/28/2016
01/19/2016
Dividend USD 0.05
01/27/2016
10/28/2015
Dividend USD 0.05
11/05/2015
07/13/2015
Dividend USD 0.05
07/21/2015
04/29/2015
Dividend USD 0.05
05/07/2015
01/15/2015
Dividend USD 0.05
01/22/2015
10/28/2014
Dividend USD 0.05
11/05/2014
07/25/2014
Dividend USD 0.05
07/31/2014
04/30/2014
Dividend USD 0.05
05/07/2014
02/05/2014
Dividend USD 0.05
02/12/2014
10/29/2013
Dividend USD 0.04
11/06/2013
07/30/2013
Dividend USD 0.03
08/08/2013
04/26/2013
Dividend USD 0.03
05/03/2013
12/13/2012
Dividend USD 0.14
12/20/2012
10/26/2012
Dividend USD 0.05
11/06/2012
07/27/2012
Dividend USD 0.05
08/03/2012
04/17/2012
Dividend USD 0.05
04/25/2012
02/10/2012
Dividend USD 0.05
02/16/2012
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SLP
Simulations Plus, Inc. is a developer of drug discovery and development software for mechanistic modeling and simulation, for machine-learning-based prediction of properties of molecules from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. The Company offers its products and services through two business segments, which include Simulations Plus, Inc. and Cognigen Corporation. Cognigen Corporation is the subsidiary of the Company. Its pharmaceutical/chemistry software is used by various companies, such as pharmaceutical, biotechnology, agrochemical, and food industry companies and to regulatory agencies for use in the conduct of industry-based research. Its clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamics modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Simulations Plus Inc stock information, including NASDAQ:SLP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLP stock methods without spending real money on the virtual paper trading platform.